KLS-13019

KLS-13019 is an orally active GPR55 receptor antagonist and a structural analogue of cannabidiol (CBD). It can prevent and reverse chemotherapy-induced peripheral neuropathy (CIPN) in a dose-dependent manner in rats .


Cat. No.: EX-A15591	Purity: >98%

	Chemical structure of KLS-13019

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
5mg	1085	in-stock
25mg	4022	in-stock
100mg	9880	in-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	1801243-39-9
Purity	>98%
Formula	C22H29NO3
Mol Weight	355.4706
Color	Off-white to gray
State	Solid
Solubility	soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder -20℃, 3 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Ippolito MJ, et al. KLS-13019, a novel structural analogue of cannabidiol (CBD) and GPR55receptor antagonist, Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Rats. J Pharmacol Exp Ther. 2024 Aug 22:JPET-AR-2024-002190.
CoA	CoA of KLS-13019

Smiles:	CC([C@@H]1CCC(C)=C[C@H]1C2=C(C=C(C=C2O)CC3CN(C3)C(C)=O)O)=C


		Search